[Successful correction of post-transplantation nephrotic syndrome with mabtera].
On March 8, 2007, a patient was admitted to the Department of Renal Transplantation, Academician B. V. Petrovsky Russian Surgery Research Center, for end-stage chronic renal failure and uremia and on March 9, 2007, he underwent cadaveric kidney allografting. In the posttransplantation period, the patient developed significant nephrotic syndrome with proteinuria being as high as 3900 mg/day. This proteinuria was regarded as a manifestation of rejection; immunosuppressive therapy was intensified: the immunosuppression protocol again included oral metipred in a dose of 60 mg/day; pulse therapy was performed. However, proteinuria remained at the same level as before. Then the authors decided to administer Mabtera. The latter was injected in a daily dose of 600 mg on June 20 and July 20, 2007. Just following 2 weeks, proteinuria decreased to 132 mg/day and persisted throughout the observation period. Therefore, Mabtera may be effectively used for the successful correction of posttransplantation nephrotic syndrome.
Goriaĭnov
V A
VA
Kaabak
M M
MM
Babenko
N N
NN
Zokoev
A K
AK
Morozova
M M
MM
Shishlo
L A
LA
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008297:Male; D009404:Nephrotic Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D011183:Postoperative Complications / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D011507:Proteinuria / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D000069283:Rituximab; D016896:Treatment Outcome; D055815:Young Adult
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab